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Ecdysoneless Overexpression Drives Mammary
Tumorigenesis through Upregulation of C-MYC and
Glucose Metabolism
Bhopal C. Mohapatra1, Sameer Mirza1, Aditya Bele1, Channabasavaiah B. Gurumurthy1, Mohsin Raza1,
Irfana Saleem2, Matthew D. Storck3, Aniruddha Sarkar1, Sai Sundeep Kollala3, Surendra K. Shukla3,
Siddesh Southekal1, Kay-Uwe Wagner3, Fang Qiu4, Subodh M. Lele5,6, Mansour A. Alsaleem7,8,
Emad A. Rakha7, Chittibabu Guda6, Pankaj K. Singh1,2,3,6, Robert D. Cardiff9, Hamid Band1,2,3,5,6, and
Vimla Band1,2,6

Ecdysoneless (ECD) protein is essential for embryogenesis,
cell-cycle progression, and cellular stress mitigation with an
emerging role in mRNA biogenesis. We have previously shown
that ECD protein as well as its mRNA are overexpressed in breast
cancer and ECD overexpression predicts shorter survival in
patients with breast cancer. However, the genetic evidence for
an oncogenic role of ECD has not been established. Here, we
generated transgenic mice with mammary epithelium-targeted
overexpression of an inducible human ECD transgene (ECDTg).
Signiﬁcantly, ECDTg mice develop mammary hyperplasia, preneoplastic lesions, and heterogeneous tumors with occasional
lung metastasis. ECDTg tumors exhibit epithelial to
mesenchymal transition and cancer stem cell characteristics.
Organoid cultures of ECDTg tumors showed ECD dependency
for in vitro oncogenic phenotype and in vivo growth when
implanted in mice. RNA sequencing (RNA-seq) analysis of

Introduction
The mammalian Ecdysoneless (ECD) is the highly conserved orthologue of Drosophila ecdysoneless (Ecd) whose mutations lead to
developmental arrest (1). Ecd interacts with the spliceosome component
pre-mRNA processing 8 (Prp8; ref. 2), and loss of Prp8 or Ecd led to
defective splicing (3). ECD associates with several RNA biogenesis
components such as DDX39A and regulates nuclear mRNA export (4),
as well as mRNA splicing machinery to regulate mRNA splicing (5).
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ECDTg tumors showed a c-MYC signature, and alterations in
ECD levels regulated c-MYC mRNA and protein levels as well as
glucose metabolism. ECD knockdown-induced decrease in glucose uptake was rescued by overexpression of mouse ECD as well
as c-MYC. Publicly available expression data analyses showed a
signiﬁcant correlation of ECD and c-MYC overexpression in
breast cancer, and ECD and c-MYC coexpression exhibits worse
survival in patients with breast cancer. Taken together, we
establish a novel role of overexpressed ECD as an oncogenesis
driver in the mouse mammary gland through upregulation of
c-MYC–mediated glucose metabolism.
Implications: We demonstrate ECD overexpression in the mammary gland of mice led to the development of a tumor progression
model through upregulation of c-MYC signaling and glucose
metabolism.
While the structure of ECD has not been determined, small
angle X-ray scattering analyses showed that the ﬁrst 400 residues
of ECD are globular and the next 100 residues exhibit an
extended cylindrical structure (6). Others and we have shown
that ECD interacts with PIH1D1 and RUVBL1 components of the
particle for arrangement of quaternary structure (PAQosome), a
novel multi-subunit cochaperone complex (7, 8). Notably, ECD,
PRPF8, and R2TP subunits are present in a single multi-protein
complex (8, 9).
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ABSTRACT
◥
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We showed that germline deletion of ECD in mice leads to
embryonic lethality and deletion of ECD in cells led to cell cycle
arrest (10). We showed a role of ECD in mitigating endoplasmic
reticulum (ER) stress (11). ECD also regulates p53 stability, either
directly (12) or through TXNIP (13), suggesting a role in genotoxic
stress response.
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ECD overexpression is frequent in several cancers, such as
breast (4, 14), pancreas (15), cervical, head and neck (5), and
gastric (16). ECD mRNA and protein overexpression in patients
with breast cancer correlate with shorter survival (4, 14). Overexpressed ECD cooperates with mutant Ras to transform immortal
human mammary epithelial cells (hMEC; ref. 17), as well as ECD
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Figure 1.
ECD overexpression promotes mammary gland hyperplasia, heterogeneous tumors, and preneoplastic lesions. A, Representative whole-mount staining images of
littermate control and mouse mammary gland in ECDTg mouse at 5 to 6 months of age. Scale bar, 400 mm; inset 1,000 mm. B, H&E staining of ECDTg tumors. Scale bar,
100 mm. C, Western blot for ECD expression (tumor numbers in Supplementary Table S1). D, Age-matched control and ECDTg mammary gland at 15 to 25 months,
inset 1,000 mm. E, H&E staining of ECDTg mammary gland. Scale bar, 400 mm; and inset 100 mm. F, Western blot for ECD protein. HSC-70, used as a loading control.
MG, mammary gland.
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Figure 2.
Characterization of ECDTg tumors by IHC. A–F, ECDTg tumor subtypes were immunostained with indicated antibodies. Scale bar, 50 mm (magniﬁcation 400!);
inset scale bar, 10 mm (magniﬁcation 1,000!).
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Materials and Methods
Detailed Materials and Methods of the following sections are
included in Supplementary Information: antibodies, media, reagents,
chemicals and cell culture, generation of Tet(O)-ECD transgenic
mouse, mammary gland harvest and whole-mount staining, tumor
organoid growth and analysis, tumor transplantation, immunohistochemistry (IHC), Western blotting, RNA isolation and real timePCR analysis, transcriptome analysis by RNA sequencing (RNA-seq)
analysis, RNA stability, metabolites extraction and mass spectrometric
metabolomics analyses, glucose uptake, METABRIC and KM Plotter
database analyses, and statistical analyses.
Tumor transplantation
ECDTg tumor fragments ("2 mm3) were placed in the cleared
mammary fat pads of recipient mice on both sides. At day 10
posttransplantation, palpable tumors were measured, and mice were
randomly assorted into two groups: with or without doxycycline þ
sucrose in drinking water. For other experiments, 2 ! 106 ECDTg
tumor-derived cells were injected orthotopically into fourth inguinal
mammary gland and tumor growth was monitored over time.
Metabolites extraction and mass spectrometric metabolomics analyses and glucose uptake
Doxycycline-inducible ECD overexpressing (ECD-OE) MCF10A
and 76NTERT cells were cultured with or without doxycycline
for 72 hours and were subjected to metabolomics analyses as
described previously (18). Similarly, ECDTg tumor organoids
grown as suspension in presence and absence of doxycycline for
96 hours were processed for metabolomics. Glucose uptake assay
was performed in following cells ECDTg organoids ($doxycycline),
doxycycline-inducible ECD-overexpression (OE; þdoxycycline)
and controls (-doxycycline) MCF10A and 76NTERT cells and

control and ECD knockdown (KD) SUM-159 cells as described
previously (4). The detailed procedures are included in Supplementary Information.
Human and animal subjects
Mice uses in this study were preapproved by the University of
Nebraska Medical Center Institutional Animal Care and Use Committee (IACUC) and is in compliance with Federal and State guidelines

Results
ECD overexpression promotes mammary hyperplasia,
preneoplastic mammary gland lesions, and tumor formation
To directly assess the role of ECD in oncogenesis, we generated
transgenic mice with germline incorporation of a Tet(O)-Flag-ECDIRES-eGFP construct, designed to regulate human ECD gene overexpression in the mouse mammary gland under doxycycline control
(Supplementary Fig. S1A). Further crossing of these mice with transgenic mice bearing an MMTV-tTA transgene (19) resulted in Tet(O)Flag-ECD-IRES-eGFP; MMTV-tTA double-transgenic mice (designated as ECDTg; Supplementary Fig. S1B).
Comparison of the mammary glands of 5 to 6 months old ECDTg
mice with single transgene-expressing age-matched littermate controls
showed increased ductal branching and lobulo-alveolar development
(Fig. 1A; Supplementary Fig. S2A) as seen with other mammary
transgenic models (20, 21). Overall, 85% (6 of 7 examined) ECDTg
mice exhibited mammary gland hyperplasia compared with none (0 of
7 mice) in control mice. Hyperplasia showed overexpression of ECD
protein and smooth muscle myosin (Supplementary Fig. S2B), a
marker of hyperplasia (22).
Notably, 33% (17 of 51) of ECDTg mice exhibited heterogeneous
tumors by 15 to 25 months of age, and 1 of these 17 mice showed lung
metastasis (Fig. 1B; Supplementary Table S1), which was positive for
ECD and CK14, patchy CK19 staining, and was negative for the Clara
cells marker CC10 (Supplementary Fig. S3). ECDTg tumors were
heterogeneous with distinct histologic subtypes (Fig. 1B), as is the case
with other genetically engineered mouse models of breast cancer, such
as C-MYC and WNT (23). Of 17 tumors, 7 were of the adenosquamous
type and 4 tumors exhibited spindle cell morphology with EMT
characteristics, 2 tumors showed solid carcinoma morphology characterized by epithelial cells arranged in sheet-like structures, 2 tumors
were papillary type characterized by projections of epithelial cells, 1
showed carcinoma with ﬁbrosis, and 1 tumor was partially necrotic
with undifferentiated histology. As anti-ECD antibodies cross-react
with human and mouse ECD, use of human ECD speciﬁc primers
showed expected human ECD mRNA in ECDTg tumors (few examples
shown in Supplementary Fig. S2C). ECDTg tumors showed expected
higher expression of ECD protein (Fig. 1C), and IHC analysis conﬁrmed ECD staining (Supplementary Fig. S2D).

Figure 3.
Organoid formation and tumor growth of ECDTg tumor-derived cells. A, Images of organoids upon doxycycline treatment. B, Western blot of lysates from organoids,
b-actin used as a loading control. C, Three independent tumors $doxycycline, insets show high magniﬁcation. Scale bar, 400 mm. D and E, Organoid number and size
after 4 days of doxycycline treatment (N ¼ 3 times and 4 wells per condition). & & , P < 0.01; & & & , P < 0.001. Data represents mean $ SEM with two tailed unpaired t test,
and nested t test. F, Western blot shows ECD expression; densitometry in respect to without doxycycline in each tumor normalized with b-actin, shown below.
G, qRT-PCR using human ECD speciﬁc primers. H, T3 organoids were injected orthotopically into 5 NSG mice. The tumor growth is plotted as tumor volume over days.
I, Images of the isolated tumors. 2 of the mice (1F and 4F) died during experiment due to unknown reason. J, tumor fragments of 2 mm3 size from T3 were transplanted
in NSG mice. After 10 days, the tumor volume was measured and mice were distributed into two groups for with and without doxycycline treatment, and growth was
monitored for the next 12 days. Mean $ SEM of tumors is calculated by mixed model of ANOVA analysis. & & & , P < 0.001. K, Images of the tumors harvested after the
dissection. L, qRT-PCR using human and mouse ECD speciﬁc primers. M, IHC of tumor sections from doxycycline-treated mice 3F, stained with indicated antibodies.
DOX, doxycycline. Lt, left; Rt, right.

AACRJournals.org

Mol Cancer Res; 20(9) September 2022

Downloaded from http://aacrjournals.org/mcr/article-pdf/20/9/1391/3197777/1391.pdf by University of Nebraska Medical Center user on 22 September 2022

cooperates with human papillomavirus (HPV)16 E7 to immortalize
keratinocytes (5).
Given the evidence for a prooncogenic role of ECD, here we
generated ECD transgenic mice [Tet(O)-ECD; MMTV-tTA, hereafter
called ECD transgene (ECDTg) mice] to target ECD overexpression in
the mouse mammary epithelium. Notably, ECDTg mice led to mammary hyperplasia followed by preneoplastic lesions or heterogenous
tumors with aging. The ECDTg mice tumors exhibited epithelial to
mesenchymal transition (EMT) and ECD dependency for in vitro
organoid growth as well as in vivo tumorigenesis upon implantation in
mice. ECDTg overexpression upregulates c-MYC mRNA and protein
expression by regulating c-MYC mRNA as well as protein stability, and
consequently affecting glucose metabolism. These ﬁndings support a
prooncogenic role of ECD overexpression in breast cancer through
upregulation of c-MYC and glucose metabolism.
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Figure 4.
RNA-seq analyses comparison of ECDTg tumors and control mammary glands. A, Principal component analysis (PCA) analysis of RNA-seq data shows clustering of
control mammary glands and ECDTg tumor datasets. First Principal component (PC1), 51.2% viability; and Second Principal component (PC2), 16.9% viability.
B, Heatmap of the top 50 differentially expressed genes among different biologic replicates of control mammary glands and tumors. Upregulated genes in red,
downregulated genes in green. C, Box plot shows the enrichment scores obtained using single sample Gene Set Enrichment Analysis of the c-MYC signature genes.
D, MYC-regulated metabolic genes in ECDTg tumors. RNA-seq followed by cluster comparison analyses of 4 tumors. 82 up- and downregulated genes are shown. Red
(upregulated) green (downregulated). E, PCA shows clustering of ECDTg tumors (n ¼ 4) based on tumor type. PC1 represent 45.5% viability and PC2 represent 34.2%
viability. F, Heatmap shows heterogeneity among the tumors. G, Heatmap depicting EMT signature upregulated in spindle cell carcinoma (Tumor#T3). H, Heatmap
displaying papillary carcinoma signature genes upregulation in papillary carcinoma (T4).

1396 Mol Cancer Res; 20(9) September 2022
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Figure 5.
ECDTg tumors exhibit upregulation of c-MYC. A, qRT-PCR shows increased c-Myc, mRNA in tumors. Bar graph shows fold change of mRNAs (controls, n ¼ 4; and
tumors, n ¼ 4). & , P < 0.05. B, Western blot with indicated antibodies. HSC-70, used as a loading control. C, IHC of indicated tumors and c-MYC staining. D and E,
Representative IHC images and qRT-PCR mRNA expression analysis of 4 independent ECDTg transplanted tumors from doxycycline-untreated or doxycyclinetreated mice. F, Western blot of lysates of organoids. HSC-70 used as a loading control. DOX, doxycycline.
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transgenic models of Metmut, retinoblastoma protein (RB) deletion
(27, 34), and MMTV-PIK3CAH1047R (35). Tumors from PIK3CA
mice were used as positive control in our experiment (Fig. 2F).
ECD overexpression is required for the maintenance of
tumorigenic phenotype of ECDTg tumors
Next, we established and characterized organoid cultures of ECDTg
tumors. Notably, doxycycline dose-dependent decrease in the levels of
ECD protein correlated with organoid forming efﬁciency (Fig. 3A
and B), organoid number, and sizes (Fig. 3C–E). Expected doxycycline-dependent decrease in ECD protein as well as human ECD
mRNA were observed (Fig. 3F and G). The long latency and low
penetrance precluded analyses using in vivo doxycycline-inducible
attenuation of the transgenic ECD expression. Therefore, ECDTg
tumor organoid-derived cells were orthotopically injected into the
mammary fat pads of athymic nude mice, similar to the literature (36).
Easily palpable tumors were observed within 1 month of injections,
and these tumors grew rapidly afterward (Fig. 3H and I). In addition,
similar to the literature (37) transplantation of ECDTg tumor fragments into NOD/SCID gamma (NSG) mice for 10 days, and then
switching 50% mice to doxycycline-containing water with further
monitoring tumor growth over 12 days showed a signiﬁcant reduction
in the tumor growth rate and ﬁnal tumor size in the doxycyclinetreated group (Fig. 3J and K). qRT-PCR analysis of mouse and
human ECD mRNA expression using human ECD speciﬁc primers
showed doxycycline-inducible decrease in human ECD mRNA
levels (Fig. 3L). IHC analysis conﬁrmed the reduction in ECD
expression in tumors from the doxycycline-treated group with a
concomitant reduction in Ki-67 staining (Fig. 3M). Histologically,
the transplanted tumors were comparable with the original tumors
(Supplementary Fig. S4).
RNA-seq analysis of ECDTg tumors reveals heterogeneity and
upregulation of MYC target metabolic genes
RNA-seq analysis of 4 ECDTg tumors (2 adenosquamous carcinoma, 1 spindle cell carcinoma, and 1 papillary) in comparison with three
control mammary glands of 6-month–old virgin female mice, followed
by principal component analysis (PCA) showed distinct clusters
corresponding to tumors and control mammary glands (Fig. 4A).
Differential gene expression (DEG) analysis showed that 2,210 genes
were differentially expressed between tumors and controls of which the
top 50 are shown as a heatmap (Fig. 4B). Notably, several genes
associated with the basal subtype of breast cancers (Trp63, CK14,
CK15, and CK17), cell-cycle regulated genes (E2F1, CENPI, Ccnb1,
Mcm5, cMyc), and histone H2B gene family members (Hist1h2bj,
Hist1h2af, Hist1h1e) were upregulated in tumor samples. Several
genes, such as Abcd2, Cidec, Plin1, Aqp7, Fabp4, Lep, and Bmp3 that

Figure 6.
c-MYC mRNA levels and protein stability upon alterations in ECD levels. Western blot of ECD and c-MYC protein, HSC-70 used as a loading control (A–C) and mRNA
by qRT-PCR (D–F) in indicated cell lines. G and H, Time-dependent mRNA expression of c-MYC upon induction of ECD. mRNA quantitation data represents mean $
SEM with two-tailed unpaired t test. n ¼ 3; & , P < 0.05; & & , P < 0.01; & & & , P < 0.001. Schematic display of the qPCR primer pairs (marked arrows) used to measure premRNA and mature mRNA species (I). Bar graphs show overexpression of ECD resulted in upregulation of c-MYC mRNA (J and K). Pre-mRNA to mRNA ratio in ECDoverexpressing cells is shown in bar graphs as fold change in comparison with controls. 18S was used for normalization (L and M). The stability of c-MYC mRNA was
analyzed in doxycycline-inducible ECD-overexpressing indicated cells in the presence or absence of doxycycline for 72 hours. The cells were treated with actinomycin
D (5 mg/mL) for indicated time points and qRT-PCR was performed after RNA isolation. GAPDH was used for normalization. Half-life of c-MYC mRNA in MCF10A (N)
and 76NTERT (O). Data represents mean$ SE of three independent experiments. The stability of c-MYC protein was analyzed in doxycycline-inducible ECDoverexpressing MCF10A cells in the presence or absence of doxycycline for 72 hours. The cells were treated with cycloheximide (50 mmol/L) for indicated time points
and lysates were collected. P, Western blot with indicated antibodies. P and R, Half-life of c-MYC protein in ECD overexpressing MCF10A cells. Q and S, c-MYC protein
stability was analyzed after 48 hours of treatment of SUM-159 with control or ECD siRNA, followed by cycloheximide (CHX) treatment. Q, Western blot shows c-MYC
protein in ECD KD cells. S, Exponential decay plot shows half-life of c-MYC upon ECD KD. Densitometry of c-MYC after normalizing to their respective loading
controls, GAPDH and b-actin in comparison with no CHX treatment are indicated on top in (P) and (Q). NS, not signiﬁcant; DOX, doxycycline; h, hours; mnts, minutes.
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Histologic analysis of the remaining 34 tumor-free ECDTg mice
revealed that 29 (85%; 57% of the overall ECDTg cohort) of these mice
exhibited abnormal mammary gland histology with distended hyperplastic alveolar nodules and lipid accumulation in the ducts and
lobules (Supplementary Table S2; Fig. 1D). Hematoxylin and eosin
(H&E) staining showed squamous metaplasia, atypical nuclei, glandular differentiation, a dense stroma, lymphocytic inﬁltration, and
dark proteinaceous staining inside alveolar lumen (Fig. 1E) similar to
other transgenic models (24), with higher levels of ECD protein
(Fig. 1F). In comparison with the ECDTg mice, only 4 of 17
(23.5%) age-matched control mice exhibited some squamous nodules
with ductal ectasia, distinct morphology from ECDTg mice derived
lesions (Supplementary Table S2) as seen in other transgenic models
(25, 26). Of the 34 ECDTg mice analyzed, 9 of 11 were parous mice and
20 of 23 were nulliparous mice that developed neoplasia, whereas only
4 of 15 nulliparous and none of 2 parous age-matched control mice had
abnormal mammary glands.
IHC showed strong positive cytokeratin (CK)14 expression in
adenosquamous tumor, spindle cell carcinoma, and carcinoma with
ﬁbrosis (Fig. 2A). Positive CK18 staining was seen in adenosquamous
carcinoma, solid carcinoma, and carcinoma with ﬁbrosis. The undifferentiated carcinoma showed only weak staining for both CK14 and
CK18. Several tumors exhibited cells with dual CK14 and CK18
staining, suggestive of the presence of progenitor cells in these tumors
(Fig. 2A merged image; ref. 27). Furthermore, nuclear p63, basal
mammary epithelial cell marker (21) and CK19, glandular epithelial
cell marker (28) staining was observed in tumors positive for CK14;
however, undifferentiated carcinoma type tumors were negative for
p63. CK19, a known marker of papillary carcinoma (21, 29) showed
strong staining in the papillary carcinoma and adenosquamous carcinoma, and patchy staining in solid carcinoma, carcinoma with
ﬁbrosis and undifferentiated carcinoma. However, spindle cell carcinoma was negative for CK19 (Fig. 2B).
About 26% of ECDTg tumors displayed the EMT phenotype,
spindle cell carcinoma showed lack of E-cadherin and upregulation
of vimentin, slug, and twist; however, carcinoma with ﬁbrosis was
positive for E-cadherin and showed upregulation of vimentin, slug,
and twist (Fig. 2C) similar to other transgenic models (30, 31). The
remaining histologic subtypes of ECDTg tumors showed E-cadherin
staining. Vimentin staining in the ﬁbrous parts of tumors was observed
in all subtypes (Fig. 2C). ECDTg tumors were highly positive for Ki-67,
irrespective of the subtypes (Fig. 2D).
A subset of reported genetically engineered mouse model (GEMM)
tumors are estrogen receptor positive (ERþ), such as cyclin D1 or
PIK3CA (32, 33). Our analysis revealed that 7 of 17 (41%) ECDTg
tumors were ERþ, with 2 tumors positive for both ER and progesterone
receptor (PR; Fig. 2E). Our results are consistent with reported
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ECDTg tumors express high MYC mRNA and protein
Analysis of tumors and organoids showed ECDTg tumors express
high levels of c-MYC mRNAs (Fig. 5A) as well as c-MYC protein
(Fig. 5B and C). Transplanted tumors showed ECD-dependent regulation of c-MYC upon doxycycline treatment (Fig. 5D and E).
Doxycycline-inducible down regulation of ECD in ECDTg organoids,
led to ECD-dependent decrease in c-MYC levels (Fig. 5F).
Next, we generated two immortal hMECs, MCF10A and 76NTERT
with doxycycline-inducible ECD overexpression. In both cell lines
a doxycycline dose-dependent increase in ECD levels led to increase
in c-MYC mRNA and protein levels (Fig. 6A, B, D, and E). Furthermore, siRNA-mediated knockdown of ECD in a breast cancer cell line
SUM-159 showed a signiﬁcant ECD-dependent decrease in c-MYC
mRNA and protein levels (Fig. 6C and F). To demonstrate the effect of
ECD on c-MYC mRNA is independent of its effect on proliferation, we
performed time-dependent doxycycline induction. We observed upregulation of c-MYC mRNA as early as 3 hours correlating with ECD
mRNA upregulation (Fig. 6G and H) excluding the proliferation effect
of ECD on c-MYC mRNA.
Based on our recent work (4, 5) and that of others (2, 3) supporting
a role of ECD in splicing of pre-mRNA to mRNA, we assessed the
ratio of mRNA over pre-mRNA in control versus ECD overexpressing
cells. ECD overexpression increased the ratio of c-MYC mRNA to
pre-mRNA (Fig. 6I–M). Next, actinomycin-D treatment of control
and doxycycline-inducible ECD overexpressing MCF10A and &
76NTERT cells showed an ECD-dependent increase of c-MYC mRNA
stability (Fig. 6N and O). Furthermore, treatment of ECDoverexpressing or ECD KD cells with cycloheximide followed by
measurement of protein levels over various time periods showed
ECD-dependent increase (in MCF10A) or decrease (in SUM-159)

stability of c-MYC protein (Fig. 6P–S). Taken together, our results
demonstrate that ECD regulates stability of both c-MYC mRNA as well
as protein.
ECD regulates the levels of glycolytic metabolites and glucose
uptake
RNA-seq analyses of ECDTg tumors showed several c-MYC regulated glucose metabolic genes (Fig. 4D and E), we thus performed
LC-MS/MS–based analysis of metabolites (18) in ECDTg organoids
derived from adenosquamous tumor T1 in the presence or absence
of doxycycline. These analyses revealed a signiﬁcant decrease in
glycolytic metabolites upon doxycycline treatment (Fig. 7A). ECD
KD (þdoxycycline) in three ECDTg organoids showed a signiﬁcant
decrease in glucose uptake (Fig. 7B and C) and ECD siRNA KD in a
breast cancer cell line showed a decrease in glucose uptake (Fig. 7D
and E). Reciprocally, inducible ECD overexpression showed increased
levels of glucose and lactate (Fig. 7F and G) and increased glucose
uptake (Fig. 7H–K). PCA analysis of ECD-OE (þdoxycycline)
and control cells (-doxycycline) using top 55 metabolites showed
differential metabolic clustering (Supplementary Fig. S5). c-MYC is
known to be an important regulator of glycolysis and glycolytic
enzymes lactate dehydrogenase A (LDHA), glucose transporter
(GLUT1), hexokinase 2 (HK2), and enolase 1 (ENO1; refs. 40, 41).
ECD dependent alteration in c-MYC mRNA and c-MYC regulated
glycolytic target genes were observed (Fig. 7L–O).
Finally, decrease in glucose uptake upon ECD siRNA-mediated
Knockdown was rescued by mouse ECD (resistant against human
ECD speciﬁc siRNA) as well as by exogenous c-MYC expression
(Fig. 7P and Q). Taken together, these results demonstrate ECD
regulates c-MYC–driven glucose metabolism and thereby glucose
uptake.
Consistent with our experimental model, gene correlation analysis
was performed to assess the correlation between ECD mRNA and
c-MYC mRNA expression in all patients with breast cancer of the
METABRIC cohort (n ¼ 1,980) and stratiﬁed PAM50 molecular
subtyped patients with breast cancer (Supplementary Fig. S6A–
S6F). Signiﬁcant correlation of ECD and c-MYC mRNA expression
in all breast cancer and various subtypes of breast cancer was observed
(Supplementary Fig. S6A–S6F). Kaplan–Meier plotter (42) and Surveillance Epidemiology and End Results (SEER) prevalence analysis of
patients with breast cancer (n ¼ 493), split on the basis of trichotomization (T1 vs. T3) with the ECD (probe set 202276_at) and cMYC
mRNA (probe set 202431_s_at) expression for relapse-free survival
(RFS) and distant metastasis-free survival (DMFS), showed while ECD
high versus low (P ¼ 0.0028) or c-MYC high versus low (P ¼ 0.038)
expression had statistically signiﬁcant difference in RFS, combined
expression of ECD þ c-MYC high versus ECD þ c-MYC low predicted

Figure 7.
Metabolomics analysis of ECDTg tumor cells. A, Organoids from ECDTg T1, with or without doxycycline for 4 days, followed by analysis of glycolytic metabolites. Bar
diagram shows the fold decrease in the levels of glycolytic metabolites. & , P < 0.05; & & , P < 0.01; & & & , P < 0.001. B, Glucose uptake in three ECDTg tumor organoids (in
triplicates). The values were normalized with respective to cell counts and depicted as compared with doxycycline-untreated organoids. Quantiﬁcation of results
from four replicates is shown as a bar graph. & , P < 0.05; & & , P < 0.02; & & & , P < 0.002. Data represents as mean $ SD and two-tailed unpaired test with Welch correction.
C, Western blot of lysates from organoids used for experiments in (A) and (B) HSC-70 used as a loading control. Densitometry of ECD in respect to without
doxycycline in each tumor, after normalizing with loading control. D, Glucose uptake in control and ECD siRNA-treated cells. E, Western blot of ECD protein, b-actin
used as a loading control. F and G, Glycolytic metabolites in hMECs upon doxycycline-inducible ECD upregulation. Bar diagram shows the fold increase in the levels of
glucose and lactate in ECD-overexpressing cells compared with control cells. H and I, Glucose uptake in ECD-overexpressing cells, normalized with respect to cell
counts and depicted in comparison with control cells. J and K, Western blot shows the levels of ECD level in cells used for experiments in (H) and (I). L, Schematic
depicts the intermediate products and enzymes of glycolysis. Red-marked are c-MYC–regulated glycolytic enzymes. PM, plasma membrane. mRNA levels of
indicated genes in cells upon ECDKD (M) or ECD overexpression (N and O). P, Glucose uptake rescue in SUM-159 cells by overexpression of HA-c-MYC or mECD-GFP
in ECD KD cells. In each case & , P < 0.05; & & , P < 0.01; & & & , P < 0.001. Data represents as mean $ SD of four replicates and two-tailed unpaired tests with Welch
correction. Q, Western blot shows expression of indicated proteins. b-actin used as a loading control. DOX, doxycycline; ctrl, control.
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are known to be downregulated in breast cancer (38) were downregulated in ECDTg tumors.
Assessment of the enrichment score using the single-sample gene
set enrichment analysis (ssGSEA) method (39), demonstrated enrichment of c-MYC signature genes in tumors (Fig. 4C), heatmap of 82 upand downregulated c-MYC-regulated genes are shown (Fig. 4D). PCA
plots identiﬁed the individual tumors as belonging to different subtypes as tumor number 3 (T3; spindle cell carcinoma) and tumor
number 4 (T4; papillary adenosquamous) were distinct from tumors
T1a and T1b (adenosquamous; Fig. 4E). We examined the presence of
tumor gene signatures associated with the squamous, EMT, and
papillary types in our data, based on a public microarray database (21).
Notably, upregulation of 12 mRNAs associated with squamous carcinoma signature (T1a and T1b tumors; Fig. 4F), 34 upregulated EMT
signature genes in the EMT subset (T3; Fig. 4G), and upregulation of
papillary signature genes (T4; Fig. 4H) were seen in ECDTg tumors.
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more signiﬁcant RFS (P ¼ 0.0013; Supplementary Fig. S6G). Notably,
while DMFS probability of ECD high versus low expression (P ¼ 0.088)
or c-MYC high versus low (P ¼ 0.14) were not statistically signiﬁcant,
combined expression of ECD þ c-MYC high versus ECD þ c-MYC low
exhibited statistically signiﬁcant differences in DMFS (P ¼ 0.013;
Supplementary Fig. S6H). Taken together, these results suggest that
combination of c-MYC and ECD gene expression may provide better
prognostic value for RFS and DMFS in patients with breast cancer.

Discussion
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The evolutionarily conserved ECD protein has emerged as a
key regulator of several basic cell biological processes, including
the cell-cycle progression (8, 10), mRNA biogenesis (2–5), and
stress responses (11), and these functional attributes together with
its overexpression in human cancers and the association of such
overexpression with shorter patient survival (4, 5, 14) support its
potential prooncogenic function. In this study, we express an
inducible ECD transgene in mouse mammary epithelium and
demonstrate that ECD overexpression by itself promotes mammary
tumorigenesis. We provide evidence that ECD overexpression leads
to upregulation of c-MYC and its metabolic target genes, which
likely mediate ECD-driven tumorigenesis.
Transgenic expression of a Tet(O)-ECD construct and crossing of
these mice to a MMTV-tTA mouse (19) allowed constitutive mammary epithelium-selective overexpression of ECD in the absence of
doxycycline (Supplementary Fig. S1). Mammary alveolar hyperplasia
in 85% of 5 to 6 months old ECDTg mice together with mammary
tumor development in about a third of ECDTg mice by 15 to 25 months
of age, with rare lung metastasis (Fig. 1; Supplementary Fig. S1–S3; and
Supplementary Table S1), provided support for an oncogenic function
of overexpressed ECD. Mammary hyperplasia was similar to that seen
with low-density lipoprotein receptor-related protein 6 (Wnt signaling
co-receptor), Ron, and Six1 transgenic mice (20, 43, 44). The low
metastatic potential is comparable with transgenic models of several
putative oncogenic drivers, including c-MYC, and WNT1 (23, 45, 46).
ECDTg tumors were highly heterogeneous with distinct histologic
subtypes, including the squamous adenocarcinoma, papillary carcinoma, spindle cell tumor, carcinoma with ﬁbrosis, solid carcinoma,
and undifferentiated adenocarcinoma (Fig. 1), similar to other GEMM
models (20, 21, 23, 27, 34). MMTV–c-MYC mice exhibit diverse
histologic subtyped tumors including squamous carcinoma, adenosquamous carcinoma, spindle cell carcinoma (EMT), solid carcinoma,
papillary, micro acinar, and mixed (23) similar to ECDTg tumors.
Most ECDTg tumors also exhibited intratumoral heterogeneity with
both squamous (CK14þ, p63þ) and epithelial (CK18þ) components
(Fig. 2) and similar to other published models (21, 30, 31). Intratumoral heterogeneity has been recognized from both clinical and
pathologic point of view in breast cancer and thought to be generated
through subclonal evolution during tumor progression (47). Such
variability within a tumor may be attributed to cancer stem cell (CSC)
theory. Our initial observations indicating potential role of ECD in
CSCs regulation may attribute to its display of intratumoral heterogeneity in ECDTg tumors. The frequent ﬁnding of spindle-shaped
morphology (30) suggested the prevalence of EMT in ECDTg tumors
and upregulation of vimentin, slug, and twist are consistent with this
(Fig. 2). Of note, 41% of tumors showed ERþ staining on a subset of
tumor cells (Fig. 2) while lacking ErbB2/HER2 overexpression, similar
to some reported GEMMs (31, 34).
RNA-seq analysis of ECDTg tumors versus normal mammary
glands identiﬁed gene expression signatures consistent with the

morphology and marker-based tumor subtypes (Fig. 4E–H). In
addition, 85% of the remaining ECDTg mice exhibited preneoplastic lesions (Fig. 1), similar to Wap-Epimorphin mice (24). Because
aging FVB mice have been reported to develop hyperplasia (25, 26),
we carefully examined our control mouse cohort and found preneoplastic lesions in only 27% of control mice, with clearly distinct
histology in control versus ECDTg mice (Supplementary Table S2).
The mammary epithelium of older FVB/N strain mice can develop
rare squamous metaplasia under chronic prolactin secretion (25, 26).
However, only 2 (out of 11 analyzed) of the tumor-bearing ECDTg
mice were parous, and hyperplastic lesions were only analyzed in
nulliparous mice (Supplementary Table S1 and S2). These ﬁndings
establish ECD as a genuine oncogenic driver/co-driver. We demonstrate that ECD expression is required to maintain the tumorigenic phenotype (Fig. 3), and tumorigenicity upon transplantation
of ECDTg tumor fragments into NSG mice (Fig. 3H and I; Supplementary Fig. S4; Fig. 3J and K).
Consistent with our previous ﬁndings that mammalian ECD is
critical for cell-cycle entry (10), ECDTg tumors exhibited high Ki-67
staining (Fig. 2D). RNA-seq analysis of ECDTg tumors showed that
genes associated with the basal subtype of breast cancer, cell cycle, and
transcription were upregulated.
Upregulation of c-MYC and c-MYC target genes in tumors (Fig. 4)
supported a potentially important role of c-MYC in mediating ECDdriven oncogenesis. Notably, a reduction in c-MYC levels upon
doxycycline-induced ECD depletion in ECDTg tumor organoids
in vitro and in tumor implants in vivo (Fig. 5D and E) together with
an increase in c-MYC mRNA and protein levels in ECDTg tumors
(Fig. 5A and B) suggested that ECD overexpression upregulates cMYC levels. Doxycycline-inducible overexpression of ECD in hMECs
further conﬁrmed the ECD dependent upregulation of c-MYC (Fig. 6).
Prevalence of EMT in ECDTg tumors and their growth as organoids,
indicative of an ECD-driven stemness program, are further consistent
with a role of c-MYC (48).
Consistent with our previous results in mammalian systems (4, 5)
and data from others using drosophila (2) which showed that ECD
promotes mRNA splicing, the overexpression of ECD promoted the
conversion of c-MYC pre-mRNA to mRNA (Fig. 6I–M) as well as cMYC mRNA stability (Fig. 6N and O). Notably, ECD also positively
regulated the c-MYC protein stability (Fig. 6P–S). Given ECD’s
interaction with the mRNA processing machinery components, its
functional role in both pre-mRNA to mRNA conversion and in mRNA
export (4, 5), it is likely that ECD-dependent stabilization of c-MYC
mRNA reﬂects the more efﬁcient processing of c-MYC mRNA into a
stable, mature form. However, the possibility that ECD might regulate
c-MYC mRNA transcription remains. Increased c-MYC mRNA levels
likely provide a major mechanism for increased c-MYC protein levels
upon ECD overexpression and vice versa. At present, ECD’s positive
role to regulate the c-MYC protein stability remains unexplained. We
speculate that ECD may regulate c-MYC protein stability through its
interaction with the R2TP cochaperone complex, which is known to
promote protein folding (8). Consistent with this speculation,
RUVBL1 and RUVBL2, two essential components of the R2TP
complex, have been shown to interact with MYC and help stabilize
it (49, 50). Taken together, our results support the idea that ECD
regulates c-MYC mRNA and protein levels to potentially mediate its
oncogenic function.
Human ECD gene was ﬁrst cloned through complementation
of growth defect in glycolytic gene transcriptional activator
(GCR2)-null yeast strain lacking a key glycolytic pathway transcriptional response, known as human suppressor GCR2 (51). Since
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